taurocholic acid has been researched along with docetaxel anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, KJ; Khatun, Z; Lee, YK; Nurunnabi, M; Reeck, GR | 1 |
| Bae, YH; Byun, Y; Cho, KJ; Khatun, Z; Lee, YK | 1 |
2 other study(ies) available for taurocholic acid and docetaxel anhydrous
| Article | Year |
|---|---|
Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Delivery Systems; Female; Heparin, Low-Molecular-Weight; Humans; Mice; Mice, Nude; Neoplasms; Taurocholic Acid; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Apoptosis; Caco-2 Cells; Cells, Cultured; Docetaxel; Extracellular Signal-Regulated MAP Kinases; Female; Heparin; Human Umbilical Vein Endothelial Cells; Humans; Intestinal Absorption; Mice; Mice, Nude; Nanoparticles; Taurocholic Acid; Taxoids; Tissue Distribution; Vascular Endothelial Growth Factor A | 2014 |